Pharmacoepidemiology and Drug Safety· 2026Q1
Prescription Intervals of Medications for Chronic Use: A Cohort Study
- 0citations
- Q1SCImago
- 2026year
Short summary
Prescription intervals for chronic medications in older Irish primary care patients cluster around 30, 60, and 90 days, with significant within-patient variation.
AI-generated from the title and abstract; the full text is not read.
Key points
- Prescription intervals for chronic medications in older Irish primary care patients primarily cluster around 30, 60, and 90 days.
- Significant heterogeneity in prescription intervals was observed mainly at the within-patient level.
- Patient-specific covariates (age, sex, healthcare cover) showed consistent associations with prescription intervals across most drug classes.
- The parametric waiting time distribution (pWTD) method effectively described the population average distribution of empirical intervals.
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Purpose In deprescribing studies, a prescription-free gap is typically used to determine if patients discontinued their treatment. An appropriate gap depends on the typical time between prescriptions during continued use. This work aims to characterise the interval between prescriptions of chronic drugs using different methods for a cohort of older people in primary care in Ireland. Methods The empirical prescription interval was analysed for 38,154 patients for the twenty most common drug classes and the association between covariates and the interval was analysed using a multi-level model. Estimates were also compared to those obtained from the parametric waiting time distribution (pWTD) approach. Results Available covariates had consistent relationships with prescription intervals across drug classes. For example, each additional prescription issue was associated with an increase in the interval by 5.0 (NSAIDs) to 19.7 days (“Other antidepressants”). Full public health cover was associated with a -29.0 day (inhaled adrenergics) to -11.0 day (opioids) change relative to partial cover, while other/private cover had a -17.9 day (benzodiazepines and associated drugs) to -7.1 day (SSRI and SNRIs) change relative to partial cover. The pWTD also produced consistent estimates of the population interval for most drugs. Conclusions The interval varied substantially within drug classes, due to a mixture of patient, practice and unmodelled factors. Variation between practices was effectively explained, with residual variation between patients and within patients. The pWTD approach is useful for describing complex distributions of intervals, and may be more appropriate for inferring a gap than summarising truncated data. Plain language summary The time between one drug prescription and the next was calculated for the 20 most commonly prescribed drug classes in a database of older people attending primary care in Ireland. The timing varied drastically among drugs, due to differences in patients and practices. We analysed these variables using two approaches. The first looked at how factors such as age, sex, and healthcare cover relate to the time between prescriptions. The second described the overall pattern of prescription intervals as a combination of simpler underlying patterns. Key points Prescription intervals are highly focussed around intervals of typical prescribed quantities, as expected, with modes of approximately 30, 60, and 90 days for all drug classes. Heterogeneity in the prescription interval for specific drug classes was found to be mainly at the within-patient level. This may be due to prescription renewal behaviour changing over time for individuals. Patient-specific covariates, such as age, sex and healthcare scheme cover had a similar effect on the prescription interval across the most frequent drug classes prescribed. The parametric waiting time distribution, using a finite mixture model to account for unmodelled variation, was able to robustly explain the population average distribution of empirical intervals using a penalised likelihood procedure.
The authors' abstract, as published at the source. Pharmacoepidemiology and Drug Safety, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Geriatrics and Gerontology
Geriatrics and GerontologyMedicine